Castle Biosciences マネジメント

マネジメント基準チェック /44

Castle Biosciencesの CEO はDerek Maetzoldで、 Sep2007年に任命され、の在任期間は 17.17年です。の年間総報酬は$ 1.61Mで、 42.7%給与と57.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.48%を直接所有しており、その価値は$ 13.52M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と4年です。

主要情報

Derek Maetzold

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	42.7%
CEO在任期間	17.2yrs
CEOの所有権	1.5%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	4yrs

経営陣の近況

Recent updates

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

CEO報酬分析

Castle Biosciences の収益と比較して、Derek Maetzold の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$6m
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$2m	US$686k	-US$57m
Sep 30 2023	n/a	n/a	-US$76m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$8m	US$660k	-US$67m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$7m	US$625k	-US$31m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$5m	US$550k	-US$10m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	US$7m
Mar 31 2020	n/a	n/a	US$6m
Dec 31 2019	US$4m	US$770k	US$3m
Sep 30 2019	n/a	n/a	US$4m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$791k	US$410k	-US$10m

報酬と市場: Derekの総報酬 ($USD 1.61M ) は、 US市場 ($USD 3.21M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Derekの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Derek Maetzold (62 yo)

17.2yrs

在職期間

US$1,605,984

報酬

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Derek Maetzold	Founder	17.2yrs	US$1.61m	1.48% $ 13.5m
Frank Stokes	CFO & Treasurer	6.9yrs	US$880.25k	0.15% $ 1.3m
Kristen Oelschlager	Chief Operating Officer	4.3yrs	US$828.48k	0.49% $ 4.4m
Tobin Juvenal	Chief Commercial Officer	4.3yrs	US$829.10k	0.21% $ 1.9m
Camilla Zuckero	Vice President of Investor Relations & Corporate Affairs	no data	データなし	データなし
Kevin Doman	Vice President of Sales	2.4yrs	データなし	データなし
Keli Greenberg	VP of Human Resources & Executive Director of Human Resources	4.3yrs	データなし	データなし
Matthew Goldberg	Senior Vice President of Medical	1.5yrs	データなし	データなし
Bernhard Spiess	Company Secretary	no data	US$1.69m	データなし

4.3yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: CSTLの経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Derek Maetzold	Founder	17.2yrs	US$1.61m	1.48% $ 13.5m
Daniel Bradbury	Independent Chairman of the Board	12.2yrs	US$305.95k	0.089% $ 814.3k
G. Cole	Independent Director	5.9yrs	US$289.20k	0.048% $ 438.3k
Tiffany Olson	Independent Director	3.5yrs	US$279.20k	0.062% $ 568.3k
Kenneth Aldape	Member of Scientific Advisory Board	no data	データなし	データなし
Howard Colman	Member of Scientific Advisory Board	no data	データなし	データなし
Kimberlee Caple	Independent Director	3.3yrs	US$276.70k	0.050% $ 454.4k
Miles Harrison	Independent Director	4.6yrs	US$285.45k	0.048% $ 438.3k
Ellen Goldberg	Independent Director	3.3yrs	US$274.20k	0.067% $ 612.8k
Rodney Cotton	Independent Director	less than a year	データなし	データなし

4.0yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: CSTLの取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

Castle Biosciences マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Founder notifies of intention to sell stock

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Board Changes

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Recent updates

Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma

Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research

Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology

Castle Biosciences: Inflection Into Profitability

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test

Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology

Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM

Consensus estimates of losses per share improve by 28%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

マネジメント基準チェック /44